Dr. Vinay Kumar Gudena, MD

Dr. Gudena practices at Cone , Annie Penn, Randolph Cancer Centers - HOPD in Greensboro, North Carolina.

Dr. Gudena's NPI, 1851374292, was assigned on November 21, 2005. Dr. Gudena graduated from Andhra Medical College NTR in 2000. Dr. Gudena's North Carolina license number on file is 201500524.

Dr. Gudena's primary practice is Cone , Annie Penn, Randolph Cancer Centers - HOPD, at 501 North Elam Avenue, Greensboro, NC 27403.

Dr. Gudena's primary practice is Cone , Annie Penn, Randolph Cancer Centers - HOPD in Greensboro, North Carolina. Dr. Gudena is also affiliated with Cone Health Moses Cone Hospital. The medical group on file is Cone Health. Dmand AI also links Dr. Gudena to 1 more hospital and 1 group practice or clinic, each named with a free account. Dr. Gudena's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gudena practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Gudena's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Gudena is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Gudena's licenses on file in 3 states: North Carolina, Ohio and South Carolina.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, deep vein thrombosis (DVT), lymphoma, neutropenia and prostate cancer among the conditions Dr. Gudena treats.

CMS data shows 749 Medicare services from Dr. Gudena across 6 procedure codes in 2024, for 393 Medicare patients. Medicare paid $41,823 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 393 Medicare patients who saw Dr. Gudena in 2024. The largest group is 65 to 74, with 180 patients. 75% of them have cancer, and 72% have high cholesterol. 7% are also on Medicaid. Their average risk score is 1.40, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Gudena's median patient age at 69, with 94% women.

In 2024, Dr. Gudena wrote 3,905 Medicare Part D claims for 854 patients. 91% of them were for generic drugs. CMS names the drug for 3,616 of them, across 41 drugs with 11 or more claims each, at $2,698,026 in total drug cost. In 2023, CMS named 3,367 claims across 35 drugs.

Dr. Gudena accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 14 papers to Dr. Gudena, published from 2013 to 2024. 2013 was the busiest year, with 2. The most frequent topics are Neoplasm Metastasis, Antineoplastic Combined Chemotherapy Protocols and Immunotherapy. Dr. Gudena has published most often in Cancer Biol Ther. Dr. Gudena's most frequent co-authors are Uzair Bashir Chaudhary, MD, Smitha S. Krishnamurthi, MD and Rajiv Agarwal.

Dmand AI links Dr. Gudena to 10 clinical trials, 7 of them phase 3 studies. 8 are still active or recruiting. Conditions studied include Breast Carcinoma In Situ, Carcinoma, Non-Small-Cell Lung and Adenocarcinoma of Lung. National Cancer Institute (NCI) sponsors the most, 7.

CMS Open Payments shows 51 general payments to Dr. Gudena from 22 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 63% of the total. Pfizer Inc. paid the most, $9,030.

Dmand AI lists 1 award for Dr. Gudena, most recently Master Faculty in 2015.

Dr. Gudena graduated from Andhra Medical College NTR in 2000. Dr. Gudena is a member of ASCO.

Dr. Gudena is in network with 19 carriers, including Excellus BlueCross BlueShield, Blue Cross Blue Shield of Michigan and Elevance. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.